Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2011-11-15 Capital/Financing Update
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Capital Raising Presentation 49 pages 1.6MB
Capital/Financing Update Classification · 95% confidence The document is titled 'Capital Raising Presentation' and contains detailed information about a pro-rata accelerated non-renounceable entitlement offer by Pharmaxis Ltd. It includes terms of the offer, underwriting details, pro-forma balance sheet impact, offer timetable, and disclaimers. The content focuses on fundraising activities, share issuance, and capital structure changes. There is no indication that this is a full financial report, audit, or earnings release. The document is a presentation prepared for investors regarding a capital raising event. Therefore, the document fits the category of 'Capital/Financing Update' (CAP). The document length is substantial (15,000 characters), indicating it is the presentation itself, not just an announcement of a report.
2011-11-15 English
Notice under section 708AA(2)(f) 2 pages 43.9KB
Capital/Financing Update Classification · 95% confidence The document is a notice under section 708AA(2)(f) of the Corporations Act 2001 regarding a pro-rata accelerated non-renounceable entitlement offer of new shares by Pharmaxis Ltd. It discusses the legal compliance and disclosure exemptions related to the share offer. The content focuses on informing about a capital raising activity and the potential effect on control of the company. The document length is 2652 characters, which is relatively short and primarily an announcement rather than a detailed report. There are no financial statements or detailed financial analysis present. Therefore, this document is best classified as a Capital/Financing Update (CAP) since it relates to a fundraising activity and share issuance notice under regulatory compliance.
2011-11-15 English
Appendix 3B 12 pages 110.8KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It details the issuance of new fully paid ordinary shares, the number of securities to be issued, the issue price, and the purpose of the issue. It also references the ASX (Australian Securities Exchange) and includes detailed information about options and securities. This type of document is a formal announcement related to capital raising and changes in the company's capital structure, specifically a new share issue. It is not a full financial report, earnings release, or management discussion, but rather a capital/financing update. Therefore, the appropriate classification is 'Capital/Financing Update' (CAP). The document length is substantial (15,000 characters), indicating it is not a brief announcement of a report publication or a regulatory filing. Confidence is high due to the clear content and format matching the CAP category.
2011-11-15 English
Letter to Optionholders 2 pages 59.5KB
Capital/Financing Update Classification · 95% confidence The document is a letter dated 16 November 2011 from Pharmaxis Ltd regarding a pro-rata accelerated non-renounceable entitlement offer to raise capital. It details the terms of the entitlement offer, eligibility criteria for shareholders, key dates, and instructions for optionholders on how to participate. The content focuses on informing shareholders about a capital raising event and the procedures to participate, rather than presenting financial results or detailed financial statements. There is no indication of this being a full financial report, earnings release, or regulatory certification. The document is an announcement about a financing activity, specifically a share entitlement offer, which fits the category of Capital/Financing Update (CAP). The document length is about 5,000 characters, and it contains substantive information about the capital raising event, not just a brief notice or a report publication announcement.
2011-11-15 English
ASX Circular - Entitlement Offer 2 pages 57.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX Circular dated 16 November 2011 regarding Pharmaxis Limited's accelerated non-renounceable entitlement offer. It details the offer structure, timetable, trading halt, record date, settlement issues, and trading issues related to the entitlement offer. The content focuses on the announcement and procedural details of a capital raising event, specifically a share entitlement offer. There are no financial statements, management discussion, or audit information present. The document is not a full financial report but an announcement of a capital/financing activity. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 4837 characters, which is sufficient to contain substantive information about the financing event rather than just a brief notice or report publication announcement.
2011-11-15 English
Pharmaxis Announces PBAC Decision on Bronchitol 2 pages 87.1KB
Regulatory Filings Classification · 95% confidence The document is a media release dated 9 November 2011 from Pharmaxis announcing the Pharmaceutical Benefits Advisory Committee (PBAC) decision regarding their drug Bronchitol. It discusses the PBAC's non-recommendation for listing Bronchitol on the Australian Pharmaceutical Benefits Scheme (PBS). The content is a public announcement about a regulatory decision affecting the company's product reimbursement status. There are no financial statements, detailed financial performance data, or management discussion of financial results. The document is not a report, transcript, or detailed presentation but a news release about a regulatory decision. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2011-11-08 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.